Affymetrix, Siemens Expand Licensing Deal for Branched DNA Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix today said that it has expanded its license agreement with Siemens Healthcare Diagnostics for its branched DNA (bDNA) technology.

The Santa Clara, Calif.-based firm now has exclusive rights to develop and sell in situ QuantiGene ViewRNA products in the in vitro diagnostic market. The products are currently for research-use only. The license also provides Affy exclusive rights to alkaline phosphatase conjugated oligonucleotides and the use of them in bDNA methods for in situ detection using Fast Red substrates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.